[Clinical analysis of early stage thrombolytic therapy with venous urokinase for acute myocardial infarction in 24 cases].
OBJECTIVE
To observe the therapeutic effect of early stage thrombolytic therapy with venous urokinase for acute myocardial infarction (AMI).


METHODS
The clinic data of 24 patients treated with early stage thrombolytic therapy with venous urokinase and 18 conventional therapy were reviewed, and the repatency of the coronary artery and T-wave inversion within 24 h after the treatment were evaluated.


RESULTS
The repatency rate of urokinase group and conventional therapy group was 62.5% and 15.0%, respectively, showing significant difference (P<0.05). Shorter delay of administration of thrombolytic therapy after infarction onset resulted in higher rate of repatency.


CONCLUSIONS
Early stage thrombolytic therapy with venous urokinase can improve the therapeutic effect and reduce the mortality rate of AMI, and is therefore recommended for clinical application.
Zhi
Shao-quan
SQ
Wangniudun Hospital of Dongguan City, Dongguan 523200, China.
D000368:Aged; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy*; D015912:Thrombolytic Therapy; D013997:Time Factors; D014568:Urokinase-Type Plasminogen Activator / Q000627:therapeutic use*
D014568:Urokinase-Type Plasminogen Activator